NMRA
Neumora Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 15 ▼ Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 stu…
- Jul 6 Trial readout: Results Pending: NMRA-335140 (Phase 3), Completed 61d ago
- Jul 17 Trial readout: Results Pending: NMRA-335140 (Phase 3), Completed 74d ago
- Jul 17 Trial readout: Results Pending: NMRA-335140 (Phase 3), Completed 72d ago
- Jul 21 Trial readout: Results Pending: NMRA-335140 (Phase 3), Completed 76d ago
- Jul 21 Trial readout: Results Pending: NMRA-335140 (Phase 3), Completed 78d ago
- Jul 27 FDA: Neumora Therapeutics Reports Favorable NMRA-215 Toxicology…
- Jul 27 ▲ Neumora Therapeutics announced favorable pre-clinical toxicology res…
- Aug 17 to Aug 21 ▼ 5 days of insider sells: $701.6K by 1 insider, avg $1.55
- Oct 30 ▼ Neumora Therapeutics received a Nasdaq deficiency notice for failing…
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $701.6K.
- InstitutionsMIXED
Q3 2026: 12 added (0 new), 13 trimmed or exited.
- Short sellersBUILDING
Short interest +24.2% to 7.01M shares. 5.1 days to cover, ≈3.7% of shares.
- TrendRANGE
36% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | TRIM | $1.6M |
| UBS Group AG | DOUBLED | $573.2K |
| Qube Research & Technologies Ltd | DOUBLED | $567.6K |
| MARSHALL WACE, LLP | TRIM | $198.3K |
| MORGAN STANLEY | TRIM | $102.0K |
| JANE STREET GROUP, LLC | TRIM | $83.0K |
| Squarepoint Ops LLC | TRIM | $80.1K |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $68.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Jul 2026| Date | Firm | Rating |
|---|---|---|
| Jul 13, 2026 | RBC Capital MAINTAIN | Outperform |
| Jun 18, 2026 | Mizuho MAINTAIN | Outperform |
| Jun 16, 2026 | Needham MAINTAIN | Buy |
| Jun 16, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Aurora Daljit Singh See Remarks Aug 21, 2026 | EXERCISE | $14.8K |
Aurora Daljit Singh See Remarks Aug 21, 2026 | SELL | $32.8K |
Aurora Daljit Singh See Remarks Aug 21, 2026 | EXERCISE | $15.2K |
Aurora Daljit Singh See Remarks Aug 21, 2026 | SELL | $33.6K |
Pinto Joshua President & CEO Aug 20, 2026 | AWARD | 500,000 sh |
Milligan Michael Lee See Remarks Aug 20, 2026 | AWARD | 175,000 sh |
Duncan Jason See Remarks Aug 20, 2026 | AWARD | 375,000 sh |
Aurora Daljit Singh See Remarks Aug 20, 2026 | EXERCISE | $48.8K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 3 press releases · 1 bullish · 4 bearish · 6 neutral- NEUTRAL SC 13G/ANov 16, 2026
Paul L. Berns filed an amended Schedule 13G disclosing beneficial ownership of 10,201,627 shares (5.4% of common stock) of Neumora Therapeutics as of September 30, 2026. The filing is an amendment to a passive stake disclosure by an insider (Berns is the CEO of Neumora).
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL PRESS-RELEASENov 16, 2026
Neumora Therapeutics reported a Q3 2026 net loss of $34.4M ($0.18 per share), narrower than the $56.8M loss in Q3 2025, but the company disclosed it needs substantial additional funding to continue operations. The press release highlighted an IND submission for NMRA-215 (NLRP3 inhibitor in…
🔒 Fresh report (last 24h), subscribers only
- BEARISH 8-KOct 30, 2026
Neumora Therapeutics received a Nasdaq deficiency notice for failing to maintain the $1.00 minimum…
Monitor the stock price trajectory over the next 180 days for any closing above $1.00. A reverse stock split proposal would likely require a shareholder vote and could appear in a proxy filing…
- NEUTRAL INST-CLUSTERSep 22, 2026
In Q2 2026, 21 institutional buyers accumulated $15.2M in NMRA while 10 sellers reduced by $10.0M…
The passive buying wave (BlackRock, Vanguard, Geode) likely reflects index rebalancing or ETF inflows, not a fundamental thesis change. The active sell-off by Millennium, Susquehanna, and Jane…
All NMRA filing & press-release reports (14)
- SC 13G/A reportNov 16, 2026
- PRESS-RELEASE reportNov 16, 2026
- 8-K reportOct 30, 2026
- INST-CLUSTER reportSep 22, 2026
- 144 reportAug 20, 2026
- 144 reportAug 17, 2026
- 8-K reportAug 14, 2026
- PRESS-RELEASE reportAug 14, 2026
- 8-K reportJul 27, 2026
- PRESS-RELEASE reportJul 27, 2026
- 8-K reportJun 15, 2026
- DEFA14A reportApr 17, 2026
- PRESS-RELEASE reportMar 30, 2026
- PRESS-RELEASE reportMar 16, 2026